

Contact Carl Berke For More Information Carl@Berkesearch.com

- **04.27.23 - Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors (PR)**
 - as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). Mr. Kim succeeds Dr. Matthias Schroff, who yesterday stepped down as Chief Executive Officer and a Class I member of the Board, and Mr. Elias D. Papadimas, who yesterday stepped down as our Chief Financial Officer. Effective as of April 26, 2023, the Board also approved the appointment of Jiyoung Hwang as a Class I director of the Board. Additionally, effective as April 26, 2023, Seung Soo Shin resigned as a Class II director and chairman of the Board. Additional information about today's announcement, including biographical information about Mr. Kim and Ms. Hwang, will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.
- **04.27.23 - Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer (PR)**
 - today announced the Company's President of Research & Chief Scientific Officer, Trevor Hallam, Ph.D., will be departing from his position effective May 31, 2023 and will immediately join the Company's Scientific Advisory Board.
- **04.17.23 - EpsilonGen announces significant expansion of management team with three new senior hires (PR)**
 - EpsilonGen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team. Nick Robbins-Cherry joins as Chief Financial Officer, Andrew Calam as Vice President of Clinical Operations and Elizabeth Hardaker as Vice President of Biology.
- **04.27.23 - RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors (medtechalert)**
 - Dr. Robert Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx. He was involved in more than 30 successful New Drug Application (NDA) approvals by the FDA and the development and launch of multiple products with annual sales exceeding \$1B. While at Schering-Plough, he served as Sr. Vice President of Worldwide Clinical Research and Chief Medical Officer. He was involved in the development of numerous cancer drugs and led the development of Remicade® (infliximab), Temodar® (temozolomide), and alpha-interferon (Intron A) through PH I-III studies, securing the first FDA approval for a biologic protein. After Merck acquired Schering-Plough in 2009, Dr. Spiegel became Chief Medical Officer at PTC Therapeutics where he led the company to EU Conditional Approval for the first drug ever approved for Duchene Muscular Dystrophy.
- **04.26.23 - Giovanni Caforio to step down as Bristol Myers CEO, with Chris Boerner named successor (endpts)**
 - Giovanni Caforio will step down as Bristol Myers Squibb's CEO on Nov. 1, the New York pharma giant said Wednesday, as part of a broader leadership shakeup. Caforio, 58, has worked at Bristol Myers since 2000 and has served as CEO since May 2015, overseeing a period of growth that included the \$74 billion acquisition of Celgene. When he steps down later this year, Caforio will serve as executive chairman, according to a news release, and Chris Boerner will take the reins as the next CEO of the \$143 billion company. Boerner has been BMS' chief commercialization officer, with the pharma naming him chief operating officer effective immediately. Boerner, 52, will take over as Bristol Myers copes with revenue losses from two of its best-selling cancer medicines in Revlimid and Abraxane. Both are now facing generic competition, and saw their combined sales drop by 33%, or roughly \$1.2 billion, in the fourth quarter of 2022. Those losses led Bristol's revenues to fall 5% last quarter compared to a year ago, but its leaders have said they are confident they can grow the business through the middle of the decade. The commercial success of some of Bristol's newer medicines like the CAR-T therapy Abecma and the psoriasis pill Sotyktu will play a crucial role in that future.
- **04.25.23 - Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors (PR)**
 - Dr. Garzone is a respected pharmaceutical executive with over 25 years of diverse experience in the industry and a significant record of achievement in drug development and leadership. During her career, she has successfully overseen the clinical development of dozens of assets driving their advancement through the clinic. She is currently the chief development officer of Anixa Biosciences, where she oversees a portfolio in oncology. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech. Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. Dr. Garzone earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh. She received her Ph.D. in Clinical Science from the University of Pittsburgh.
- **04.25.23 - Rectify Pharmaceuticals Appoints Sachiyo Minegishi as Chief Operating Officer (PR)**
 - Ms. Minegishi brings 20 plus years' experience in the biotechnology industry. She most recently served as Chief Financial Officer at Akouos, Inc., where she helped lead the acquisition of the company by Eli Lilly. Previously, Ms. Minegishi was Vice President, Global Program Lead at bluebird bio and in charge of leading cross-functional teams through global development for a portfolio of gene therapies for Sickle Cell Disease. Earlier, Ms. Minegishi held leadership roles at Aegerion Pharmaceuticals, Human Genome Sciences, Genzyme, and Amgen. She began her career in investment banking at Merrill Lynch, with a focus on execution of equity financing and mergers and acquisitions in the biotechnology industry. Ms. Minegishi earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.

- 04.25.23 - Frontage welcomes Dr. James Huang as VP of Corporate Quality Assurance ([PR](#))
 - James began his career with MDS, a CRO, and has worked with leading consulting and service providers including Deloitte and Almac Group. During his time with Deloitte, he provided guidance and advice to life science companies on quality and compliance matters. At Almac Group, he held the position of Head of Quality and Regulatory Compliance overseeing the development and implementation of quality systems across locations. In his most recent role as the Global Head of Quality Assurance and Regulatory Compliance at Nestle Health Science, James was responsible for transforming the quality operation into a highly productive, globally harmonized, digitally driven, and paperless organization. He led the development and implementation of new quality systems and processes and oversaw the integration of new digital technologies to improve efficiency and compliance. James's leadership and vision were critical in achieving operational excellence, as evidenced by successful regulatory inspections and audits.
- 04.24.23 - Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors ([PR](#))
 - Dr. Dansey has dedicated his career to the development of innovative cancer therapies. Prior to joining Seagen, Dr. Dansey held senior leadership roles at Merck, Gilead Sciences and Amgen. Dr. Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.
- 04.24.23 - ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer ([PR](#))
 - Ms. Kalofonos joins ImmunoGen from Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. She also led all commercial franchises of prescription products. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise - a 2.5 billion dollar business. In this role she oversaw the global blockbuster launch of TAKHZYRO® (lanadelumab-flyo). Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals. Ms. Kalofonos received a BS from Pontificia Universidad Javeriana and an MBA from Babson College.
- 04.24.23 - HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER ([PR](#))
 - Dr. Dayno joined Harmony as Chief Medical Officer and Executive Vice President when the company was founded in 2017 and has been serving as Interim President and CEO since January 6, 2023.